Pink Sheet - News And Expert Analysis On Pharma Policy And Regulation since 1939

The Germany-based family-owned company, which has posted a decent set of financials for 2025 driven by Jardiance and Ofev, is particularly concerned about the red tape involved in getting clinical trials off the ground.

Country still trying to encourage shots after nationwide probe into post symptoms led to a long halt, but rates remain low.

Jiuyuan Gene’s semaglutide biosimilar hits unexpected regulatory roadblock on its way to market in China for type 2 diabetes over data protection provisions under "agreements between Chinese and foreign governments."

340B hospitals are preparing for the US Medicare program to reduce payments for drugs purchased at the discounted price next year, as well as planning for a potential revival of a rebate model.

April opens with US FDA goal dates for cell therapies from Replimune and Orca Bio, then momentum moves to the drugs center with Merck HIV combo, Axsome's Auvelity for Alzheimer's agitation and a trio of Sanofi applications including a hyaluronidase-free subcutaneous Sarclisa

Marketing authorization holders for selected critical medicines will face new data submission requirements as the European Medicines Agency rolls out an analytics‑based framework to assess supply chain vulnerabilities in 2026.